Carregant...

Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes

BACKGROUND: This 4-week, phase 3b, multicenter, open-label, single-arm, outpatient study demonstrated the safe and effective use of the dulaglutide single-dose pen containing 0.5 mL of placebo for subcutaneous injection in injection-naïve adult patients with type 2 diabetes (T2D), with A1C ≤ 8.5% (6...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Diabetes Sci Technol
Autors principals: Matfin, Glenn, Van Brunt, Kate, Zimmermann, Alan G., Threlkeld, Rebecca, Ignaut, Debra A.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4667342/
https://ncbi.nlm.nih.gov/pubmed/25901022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296815583059
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!